{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:18:32Z","timestamp":1791728312045,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Almirall S.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12876-019-0985-1","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T17:29:32Z","timestamp":1557250172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries"],"prefix":"10.1186","volume":"19","author":[{"name":"on behalf of the IBIS-C Study group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3206-6704","authenticated-orcid":false,"given":"Jan","family":"Tack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Stanghellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferm\u00edn","family":"Mearin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yiannakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Layer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Coffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Simren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Mackinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwen","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Marciniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"key":"985_CR1","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","volume":"130","author":"GF Longstreth","year":"2006","unstructured":"Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480\u201391.","journal-title":"Gastroenterology."},{"key":"985_CR2","doi-asserted-by":"publisher","unstructured":"Sperber AD, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut. 2016. \n                    https:\/\/doi.org\/10.1136\/gutjnl-2015-311240\n                    \n                  .","DOI":"10.1136\/gutjnl-2015-311240"},{"key":"985_CR3","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","volume":"150","author":"BE Lacy","year":"2016","unstructured":"Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel Disorders. Gastroenterology. 2016;150:1393\u2013407.e5.","journal-title":"Gastroenterology."},{"key":"985_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1046\/j.1572-0241.2003.04023.x","volume":"99","author":"F Mearin","year":"2004","unstructured":"Mearin F, Bar\u00f3 E, Roset M, Bad\u00eda X, Z\u00e1rate N, P\u00e9rez I. Clinical patterns over time in irritable bowel syndrome: symptom instability and severity variability. Am J Gastroenterol. 2004;99:113\u201321.","journal-title":"Am J Gastroenterol"},{"key":"985_CR5","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1365-2036.2011.04948.x","volume":"35","author":"AL Engsbro","year":"2012","unstructured":"Engsbro AL, Simren M, Bytzer P. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification. Aliment Pharmacol Ther. 2012;35:350\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"985_CR6","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/ajg.2011.170","volume":"106","author":"SR Weinland","year":"2011","unstructured":"Weinland SR, Morris CB, Hu Y, Leserman J, Bangdiwala SI, Drossman DA. Characterization of episodes of irritable bowel syndrome using ecological momentary assessment. Am J Gastroenterol. 2011;106:1813\u201320.","journal-title":"Am J Gastroenterol"},{"key":"985_CR7","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/ajg.2011.201","volume":"106","author":"DA Drossman","year":"2011","unstructured":"Drossman DA, Chang L, Bellamy N, Gallo-Torres HE, Lembo A, Mearin F, et al. Severity in irritable bowel syndrome: a Rome Foundation working team report. Am J Gastroenterol. 2011;106:1749\u201359 quiz 1760.","journal-title":"Am J Gastroenterol"},{"key":"985_CR8","doi-asserted-by":"publisher","unstructured":"Hungin AP, Tack J, Mearin F, Whorwell J, Dennis E, Barghout V. Irratable bowel syndrome (IBS): prevalence and impact in the USA - the truth in IBS (T-IBS) survey. Am J Gastroenterol. 2002. \n                    https:\/\/doi.org\/10.1016\/S0002-9270(02)05337-6\n                    \n                  .","DOI":"10.1016\/S0002-9270(02)05337-6"},{"key":"985_CR9","doi-asserted-by":"publisher","first-page":"860","DOI":"10.7326\/0003-4819-134-9_Part_2-200105011-00010","volume":"134","author":"F Creed","year":"2001","unstructured":"Creed F, Ratcliffe J, Fernandez L, Tomenson B, Palmer S, Rigby C, et al. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med. 2001;134:860\u20138.","journal-title":"Ann Intern Med"},{"key":"985_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000007593","volume":"60","author":"BA Hahn","year":"1999","unstructured":"Hahn BA, Yan S, Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion. 1999;60:77\u201381.","journal-title":"Digestion."},{"key":"985_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2165\/00019053-200220070-00003","volume":"20","author":"RL Akehurst","year":"2002","unstructured":"Akehurst RL, Brazier JE, Mathers N, O\u2019Keefe C, Kaltenthaler E, Morgan A, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. PharmacoEconomics. 2002;20:455\u201362.","journal-title":"PharmacoEconomics."},{"key":"985_CR12","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1097\/00042737-200212000-00007","volume":"14","author":"SA M\u00fcller-Lissner","year":"2002","unstructured":"M\u00fcller-Lissner SA, Pirk O. Irritable bowel syndrome in Germany. A cost of illness study. Eur J Gastroenterol Hepatol. 2002;14:1325\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"985_CR13","doi-asserted-by":"crossref","unstructured":"Le Pen C, Ruszniewski P, Gaudin A-F, Amouretti M, Bommelaer G, Frexinos J, et al. The burden cost of French patients suffering from irritable bowel syndrome. Scand J Gastroenterol. 2004;39:336\u201343.","DOI":"10.1080\/00365520310008458"},{"key":"985_CR14","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.clinthera.2006.10.010","volume":"28","author":"P Par\u00e9","year":"2006","unstructured":"Par\u00e9 P, Gray J, Lam S, Balshaw R, Khorasheh S, Barbeau M, et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from logic (longitudinal outcomes study of gastrointestinal symptoms in Canada), a naturalistic study. Clin Ther. 2006;28:1726\u201335.","journal-title":"Clin Ther"},{"key":"985_CR15","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1038\/533S107a","volume":"533","author":"BE Lacy","year":"2016","unstructured":"Lacy BE. Perspective: an easier diagnosis. Nature. 2016;533:S107.","journal-title":"Nature."},{"key":"985_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ajg.2015.67","volume":"110","author":"JJ Heidelbaugh","year":"2015","unstructured":"Heidelbaugh JJ, Stelwagon M, Miller SA, Shea EP, Chey WD. The Spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden. Am J Gastroenterol. 2015;110:580\u20137.","journal-title":"Am J Gastroenterol"},{"key":"985_CR17","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","volume":"10","author":"RM Lovell","year":"2012","unstructured":"Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712\u201321 e4.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"985_CR18","first-page":"8898","volume":"20","author":"KA Jadallah","year":"2014","unstructured":"Jadallah KA, Kullab SM, Sanders DS. Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol WJG. 2014;20:8898\u2013909.","journal-title":"World J Gastroenterol WJG"},{"key":"985_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2036.2006.02938.x","volume":"24","author":"J Tack","year":"2006","unstructured":"Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome \u2013 a European perspective. Aliment Pharmacol Ther. 2006;24:183\u2013205.","journal-title":"Aliment Pharmacol Ther"},{"key":"985_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/apt.12604","volume":"39","author":"P Layer","year":"2014","unstructured":"Layer P, Stanghellini V. Review article: linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2014;39:371\u201384.","journal-title":"Aliment Pharmacol Ther"},{"key":"985_CR21","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s10198-015-0747-0","volume":"17","author":"M Fisher","year":"2016","unstructured":"Fisher M, Walker A, Falqu\u00e9s M, Moya M, Rance M, Taylor D, et al. Cost-effectiveness of linaclotide compared to antidepressants in the treatment of irritable bowel syndrome with constipation in Scotland. Eur J Health Econ. 2016;17:1091\u2013100.","journal-title":"Eur J Health Econ"},{"key":"985_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","volume":"11","author":"CY Francis","year":"1997","unstructured":"Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11:395\u2013402.","journal-title":"Aliment Pharmacol Ther"},{"key":"985_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1365-2036.2004.02091.x","volume":"20","author":"MC Reilly","year":"2004","unstructured":"Reilly MC, Bracco A, Ricci J-F, Santoro J, Stevens T. The validity and accuracy of the work productivity and activity impairment questionnaire--irritable bowel syndrome version (WPAI:IBS). Aliment Pharmacol Ther. 2004;20:459\u201367.","journal-title":"Aliment Pharmacol Ther"},{"key":"985_CR24","first-page":"382","volume":"20","author":"JA Doshi","year":"2014","unstructured":"Doshi JA, Cai Q, Buono JL, Spalding WM, Sarocco P, Tan H, et al. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. J Manag Care Pharm JMCP. 2014;20:382\u201390.","journal-title":"J Manag Care Pharm JMCP"},{"key":"985_CR25","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1007\/s10620-005-3047-1","volume":"50","author":"JA Cole","year":"2005","unstructured":"Cole JA, Yeaw JM, Cutone JA, Kuo B, Huang Z, Earnest DL, et al. The incidence of abdominal and pelvic surgery among patients with irritable bowel syndrome. Dig Dis Sci. 2005;50:2268\u201375.","journal-title":"Dig Dis Sci"},{"key":"985_CR26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1177\/0958928709344247","volume":"19","author":"C Wendt","year":"2009","unstructured":"Wendt C. Mapping European healthcare systems: a comparative analysis of financing, service provision and access to healthcare. J Eur Soc Policy. 2009;19:432\u201345.","journal-title":"J Eur Soc Policy"},{"key":"985_CR27","doi-asserted-by":"publisher","first-page":"i22","DOI":"10.1136\/qshc.2008.029355","volume":"18","author":"E Spencer","year":"2009","unstructured":"Spencer E, Walshe K. National quality improvement policies and strategies in European healthcare systems. Qual Saf Health Care. 2009;18:i22\u20137.","journal-title":"Qual Saf Health Care"},{"key":"985_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.healthpol.2013.11.008","volume":"115","author":"A Reeves","year":"2014","unstructured":"Reeves A, McKee M, Basu S, Stuckler D. The political economy of austerity and healthcare: cross-national analysis of expenditure changes in 27 European nations 1995\u20132011. Health Policy. 2014;115:1\u20138.","journal-title":"Health Policy"},{"key":"985_CR29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.dld.2006.05.009","volume":"38","author":"EMM Quigley","year":"2006","unstructured":"Quigley EMM, Bytzer P, Jones R, Mearin F. Irritable bowel syndrome: the burden and unmet needs in Europe. Dig Liver Dis. 2006;38:717\u201323.","journal-title":"Dig Liver Dis"},{"key":"985_CR30","doi-asserted-by":"crossref","unstructured":"DiBonaventura M, Prior M, Prieto P, Fortea J. Burden of constipation-predominant irritable bowel syndrome (IBS-C) in France, Italy, and the United Kingdom. Clin Exp Gastroenterol. 2012;5:203\u201312.","DOI":"10.2147\/CEG.S35568"},{"key":"985_CR31","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1111\/apt.12532","volume":"38","author":"S Sethi","year":"2013","unstructured":"Sethi S, Wadhwa V, LeClair J, Mikami S, Park R, Jones M, et al. In-patient discharge rates for the irritable bowel syndrome \u2013 an analysis of national trends in the United States from 1997 to 2010. Aliment Pharmacol Ther. 2013;38:1338\u201346.","journal-title":"Aliment Pharmacol Ther"},{"key":"985_CR32","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3111\/13696998.2014.919926","volume":"17","author":"A Guerin","year":"2014","unstructured":"Guerin A, Carson RT, Lewis B, Yin D, Kaminsky M, Wu E. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population. J Med Econ. 2014;17:577\u201386.","journal-title":"J Med Econ"},{"key":"985_CR33","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/archinte.163.8.929","volume":"163","author":"SA Leong","year":"2003","unstructured":"Leong SA, Barghout V, Birnbaum HG, et al. The economic consequences of irritable bowel syndrome: a us employer perspective. Arch Intern Med. 2003;163:929\u201335.","journal-title":"Arch Intern Med"},{"key":"985_CR34","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.bpg.2013.09.003","volume":"27","author":"DW Mapel","year":"2013","unstructured":"Mapel DW. Functional disorders of the gastrointestinal tract: cost effectiveness review. Best Pract Res Clin Gastroenterol. 2013;27:913\u201331.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"985_CR35","first-page":"143","volume":"55","author":"Y-HA Shen","year":"2009","unstructured":"Shen Y-HA, Nahas R. Complementary and alternative medicine for treatment of irritable bowel syndrome. Can Fam Physician. 2009;55:143\u20138.","journal-title":"Can Fam Physician"},{"key":"985_CR36","first-page":"289","volume":"7","author":"JL Buono","year":"2014","unstructured":"Buono JL, Tourkodimitris S, Sarocco P, Johnston JM, Carson RT. Impact of Linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials. Am Health Drug Benefits. 2014;7:289\u201397.","journal-title":"Am Health Drug Benefits"},{"key":"985_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1365-2036.2005.02577.x","volume":"22","author":"MC Reilly","year":"2005","unstructured":"Reilly MC, Barghout V, Mcburney CR, Niecko TE. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2005;22:373\u201380.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-0985-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-019-0985-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-0985-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T23:12:14Z","timestamp":1588720334000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-019-0985-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["985"],"URL":"https:\/\/doi.org\/10.1186\/s12876-019-0985-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,7]]},"assertion":[{"value":"25 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The following ethics committees approved the trial protocol and its amendments: Comit\u00e9 Consultatif sur le Traitement de l\u2019Information en mati\u00e8re de Recherche dans le domaine de la Sant\u00e9 (Paris, France), Israelitisches Krankenhaus (Hamburg, Germany), University of Bologna (Bologna, Italy), Humanitas Hospital IRCS (Milano, Italy), Floraspe Renzetti Hospital (Lanciano, Italy), Agostino Gemelli University Hospital (Rome, Italy), University of Parma (Parma, Italy), University of Pisa (Pisa, Italy), University of Pescara (Pescara, Italy), Careggi University (Firence, Italy), University of Napoli Federico II (Napoli, Italy), University of L\u2019Aquila (L\u2019Aquila, Italy), University of Messina (Messina, Italy), University of Genoa (Genoa, Italy). Ospedale <i>S. Maria<\/i> di Ca\u2032 Foncello (Treviso, Italy), Fondazione IRCCS Policlinico San Matteo (Pavia, Italy), Centro m\u00e9dico Teknon (Barcelona, Spain), Hospital Cl\u00ednico San Carlos (Madrid, Spain), Hospital Universitario 12 de Octubre (Madrid, Spain), Hospital Germans Trias I Pujol (Badalona, Spain), Hospital de Bellvitge (Barcelona, Spain), Consorci Sanitari del Maresme (Matar\u00f3, Spain), Hospital Universitario Virgen de la Macarena (Sevilla, Spain), Hospital Universitari Doctor Josep Trueta (Girona, Spain), Hospital Universitari Sant Joan de Reus (Reus, Spain), National Institute for Health Research (London, UK).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JT receives grants and\/or research support from Abbott, Novartis and Shire; honoraria and\/or consultancy fees from Almirall, AstraZeneca, Danone, GI Dyamics, GlaxoSmithKline, Ironwood, Janssen, Menarini, Novartis, Rhythm, Shire, Takeda, Theravance, Tsumura, Will Pharma and Zeria; and speaker fees from Abbott, Almirall, AstraZeneca, Janssen, Menarini, Novartis, Shire, Takeda and Zeria.VS receives grants and\/or research support from Alfa Wassermann, Almirall, Aptalis, Italchimici, Norgine, Shire, Takeda, Valeas; honoraria and\/or consultancy fees from Abbott, Alfa Wasserman, Almirall, Angelini, Aptalis, CM&D Pharma, Farmaderma, Ironwood, Norgine, Shire, Takeda, Valeas, Vibrant and Zeria.FM receives speaker fees from Almirall.YY receives grants from Shire; Medtronic; and speaker fees from Almirall, Shire, and Sucampo.PL receives financial support from Abbott \/ Solvay, Almirall, Aptalis \/ Axcan, Norgine, and Shire.BC receives honoraria and\/or consultancy fees from Almirall, Mundipharma, Mayoly Spindler, and Menarini.MS receives unrestricted research grants from Danone, and AstraZeneca; consultant and\/or Advisory Board member fees from Danone, Nestl\u00e9, Chr Hansen, Almirall, Albireo and Shire; participation fees for company-sponsored speaker\u2019s bureau from Almirall, Shire, Tillotts and Takeda.JM is an employee of TFS Develop S.L, contracted by Almirall S.A to conduct the study.GW and AM are employees of Allergan International.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"69"}}